A360
Key Takeaways✦ Atlas AI
01
Mounjaro, a weekly injectable for type 2 diabetes, carries an FDA boxed warning due to a potential thyroid cancer risk observed in animal studies, though human risk is unconfirmed.
02
Patients with a history of medullary thyroid carcinoma or MEN 2 syndrome are cautioned against Mounjaro use, highlighting the importance of pre-screening for specific risk factors.
03
While Mounjaro effectively manages blood sugar, users must monitor for symptoms like neck lumps and be aware of common gastrointestinal side effects and serious risks like pancreatitis.
Atlas AI
Mounjaro (tirzepatide) is a prescription medication approved for managing blood sugar in adults and children aged 10 and older with type 2 diabetes. It is administered via weekly subcutaneous injections.
The medication carries a boxed warning from the FDA regarding an increased risk of thyroid cancer, specifically medullary thyroid carcinoma (MTC), observed in animal studies. It is not yet established if this risk extends to humans.
Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are advised against using Mounjaro. Monitoring for symptoms such as neck lumps, difficulty swallowing, or hoarseness is .
Common side effects include gastrointestinal issues like nausea and diarrhea. Serious potential side effects include pancreatitis and gallbladder problems.
Mounjaro is not FDA-approved for weight loss, though some patients may experience it.
